(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
Reports positive outcomes from trial of Imfinzi : AstraZeneca
AstraZeneca’s Phase III MATTERHORN trial showed positive results for Imfinzi (durvalumab) combined with FLOT chemotherapy in patients with resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers. The perioperative treatment improved event-free survival (EFS), the trial’s primary endpoint.
In the double-blind, placebo-controlled study, 948 participants received a neoadjuvant combination of Imfinzi and chemotherapy before surgery, followed by post-surgery treatment with Imfinzi and chemotherapy. The trial spanned 176 centers across 20 countries.
A strong trend toward improved overall survival was observed, though this secondary endpoint will be formally analyzed later. The safety profile of the Imfinzi-based regimen was consistent with known profiles of each drug, with no new safety concerns.
This trial is the first of its kind to demonstrate significant improvement in EFS for gastric and GEJ cancers, marking an important step in early-stage cancer treatment.
13-03-2025